| Name | Hikma Pharmaceuticals |
|---|---|
| Epic | HIK |
| Isin | GB00B0LCW083 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1,823.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £4,044.99 | Debt ratio | n/a |
| Shares in issue | 221.89 | Debt-to-equity ratio | n/a |
| P/E ratio | 11.9 | Assets / equity ratio | n/a |
| Total dividends per share | 36.00¢ | Price to book value | n/a |
| Dividend yield | 3 | ROCE | 24.32 |
| Dividend cover | 2.8 | EPS growth | n/a |
| Earning per share | 162 | 52-week high / low | 1,592.00p / 2,340.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Interim | 2025-08-14 | 2025-09-18 | 36.00¢ |
| Final | 2025-03-20 | 2025-05-01 | 48.00¢ |
| Interim | 2024-08-15 | 2024-09-20 | 32.00¢ |
| Final | 2024-03-21 | 2024-05-03 | 47.00¢ |
| Interim | 2023-08-10 | 2023-09-15 | 25.00¢ |
| Final | 2023-03-23 | 2023-05-05 | 37.00¢ |
| Interim | 2022-08-18 | 2022-09-20 | 19.00¢ |
| Final | 2022-03-17 | 2022-04-28 | 36.00¢ |
| Interim | 2021-08-19 | 2021-09-20 | 18.00¢ |
| Company name | Hikma Pharmaceuticals |
|---|---|
| Address | 1 New Burlington Place, London,United Kingdom, W1S 2HR |
| Telephone | +44 (0)20 7399 2760 |
| Website | http://www.hikma.com |
| Director | Position |
|---|---|
| Mr Riad Mishlawi | CEO |
| Mr Ali Al-Husry | Non-Executive Director |
| Mr Said Darwazah | Executive Chairman |
| Ms Victoria Hull | Senior Independent Director |
| Mrs Cynthia Schwalm | Independent Non-Executive Director |
| Ms Laura Balan Balan | Independent Non-Executive Director |
| Mr Douglas Hurt | Independent Non-Executive Director |
| Ms Deneen Vojta | Independent Non-Executive Director |
| Ms Mary (Nina) Henderson | Independent Non-Executive Director |
| Mr Mazen Darwazah | Executive Vice Chairman |
| Assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 1156 | 1100 | 1124 |
| Investments and other non-current assets | 11 | 10 | 10 |
| Total non-current assets | 2870 | 2580 | 2472 |
| Inventory / work in progress | 986 | 891 | 776 |
| Trade and other receivables | 949 | 824 | 841 |
| Cash and equivalents | 188 | 205 | 270 |
| Other current assets and asset held for resale | 140 | 169 | 112 |
| Total of all assets | 5133 | 4680 | 4471 |
| Liabilities $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 1978 | 1339 | 1077 |
| Long term liabilities | 834 | 1132 | 1246 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 2812 | 2471 | 2323 |
| Net assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 2321 | 2209 | 2148 |
| Equity $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 40 | 40 | 40 |
| Minority interests | 11 | 11 | 13 |
| Retained earnings | 2362 | 2158 | 2092 |
| Share premium account | 282 | 282 | 282 |
| Total equity | 2321 | 2209 | 2148 |
| Income $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 612 | 367 | 282 |
| Pre-tax profit | 455 | 281 | 233 |